Generation and characterization of a monoclonal antibody that cross-reacts with the envelope protein from the four dengue virus serotypes

• Published in: APMIS : acta pathologica, microbiologica et immunologica Scandinavica Vol. 121; no. 9; pp. 848 - 858
• Main Authors: León-Juárez, Moisés, García-Cordero, Julio, Santos-Argumedo, Leopoldo, Romero-Ramírez, Héctor, García-Machorro, Jazmín, Bustos-Arriaga, José, Gutiérrez-Castañeda, Benito, Sepúlveda, Nicolás V., Mellado-Sánchez, Gabriela, Cedillo-Barrón, Leticia
• Format: Journal Article
• Language: English
• Published: Denmark Blackwell Publishing Ltd 01.09.2013; Wiley Subscription Services, Inc
• Subjects: Aedes; Amino Acid Sequence; Animals; Antibodies, Monoclonal - biosynthesis; Antibodies, Monoclonal - immunology; Antibodies, Viral - biosynthesis; Antibodies, Viral - immunology; Cell Line; Cercopithecus aethiops; Cricetinae; Cross Reactions; Dengue virus; Dengue Virus - classification; Dengue Virus - genetics; Dengue Virus - immunology; dengue viruse-envelope protein; Epitope Mapping; Epitopes - genetics; Epitopes - immunology; Escherichia coli - genetics; Flavivirus; Mice; Mice, Inbred BALB C; Molecular Sequence Data; Molecular Typing; monoclonal antibody; Proteins; Recombinant Fusion Proteins - genetics; Recombinant Fusion Proteins - immunology; Vero Cells; Viral Envelope Proteins - analysis; Viral Envelope Proteins - genetics; Viral Envelope Proteins - immunology; Dengue virus; monoclonal antibody; dengue viruse-envelope protein
• ISSN: 0903-4641; 1600-0463
• DOI: 10.1111/apm.12044

Dengue viruses (DENVs; serotypes 1–4) are members of the flavivirus family. The envelope protein (E) of DENV has been defined as the principal antigenic target in terms of protection and diagnosis. Antibodies that can reliably detect the E surface glycoprotein are necessary for describing and mapping new DENV epitopes as well as for developing more reliable and inexpensive diagnostic assays. In this study, we describe the production and characterization of a monoclonal antibody (mAb) against a recombinant DENV‐2 E protein that recognizes a sequential antigen in both native and recombinant form located in domain II of the E protein of all four DENV serotypes. We confirmed that this mAb, C21, recognizes a sequence located in the fusion peptide. In addition, C21 does not have neutralizing activity against DENV‐2 in an in vitro system. Furthermore, the C21 mAb is an ideal candidate for the development of research reagents for studying DENV biology because it cross‐reacts with the four dengue serotypes.